122 related articles for article (PubMed ID: 15268664)
41. Preferential replication of systemically delivered oncolytic vaccinia virus in focally irradiated glioma xenografts.
Advani SJ; Buckel L; Chen NG; Scanderbeg DJ; Geissinger U; Zhang Q; Yu YA; Aguilar RJ; Mundt AJ; Szalay AA
Clin Cancer Res; 2012 May; 18(9):2579-90. PubMed ID: 22379115
[TBL] [Abstract][Full Text] [Related]
42. [Oncolytic viruses for genetic therapy of gastrointestinal tumors].
Bitzer M; Lauer UM
Z Gastroenterol; 2003 Jul; 41(7):667-74. PubMed ID: 12858239
[TBL] [Abstract][Full Text] [Related]
43. Selectively replicating oncolytic adenoviruses as cancer therapeutics.
Yu DC; Working P; Ando D
Curr Opin Mol Ther; 2002 Oct; 4(5):435-43. PubMed ID: 12435044
[TBL] [Abstract][Full Text] [Related]
44. Virus, Oncolytic Virus and Human Prostate Cancer.
Liu GB; Zhao L; Zhang L; Zhao KN
Curr Cancer Drug Targets; 2017; 17(6):522-533. PubMed ID: 27993115
[TBL] [Abstract][Full Text] [Related]
45. Oncolytic virus therapy using genetically engineered herpes simplex viruses.
Todo T
Front Biosci; 2008 Jan; 13():2060-4. PubMed ID: 17981691
[TBL] [Abstract][Full Text] [Related]
46. Eradication of solid human breast tumors in nude mice with an intravenously injected light-emitting oncolytic vaccinia virus.
Zhang Q; Yu YA; Wang E; Chen N; Danner RL; Munson PJ; Marincola FM; Szalay AA
Cancer Res; 2007 Oct; 67(20):10038-46. PubMed ID: 17942938
[TBL] [Abstract][Full Text] [Related]
47. Defining Effective Combinations of Immune Checkpoint Blockade and Oncolytic Virotherapy.
Rojas JJ; Sampath P; Hou W; Thorne SH
Clin Cancer Res; 2015 Dec; 21(24):5543-51. PubMed ID: 26187615
[TBL] [Abstract][Full Text] [Related]
48. Oncolytic biotherapy: a novel therapeutic plafform.
Hawkins LK; Lemoine NR; Kirn D
Lancet Oncol; 2002 Jan; 3(1):17-26. PubMed ID: 11905600
[TBL] [Abstract][Full Text] [Related]
49. Advanced new strategies for metastatic cancer treatment by therapeutic stem cells and oncolytic virotherapy.
Park GT; Choi KC
Oncotarget; 2016 Sep; 7(36):58684-58695. PubMed ID: 27494901
[TBL] [Abstract][Full Text] [Related]
50. Oncolytic Herpes Simplex Virus Vectors Fully Retargeted to Tumor- Associated Antigens.
Uchida H; Hamada H; Nakano K; Kwon H; Tahara H; Cohen JB; Glorioso JC
Curr Cancer Drug Targets; 2018; 18(2):162-170. PubMed ID: 28176649
[TBL] [Abstract][Full Text] [Related]
51. Oncolytic measles viruses for cancer therapy.
Nakamura T; Russell SJ
Expert Opin Biol Ther; 2004 Oct; 4(10):1685-92. PubMed ID: 15461580
[TBL] [Abstract][Full Text] [Related]
52. Replicating and host-restricted non-replicating vaccinia virus vectors for vaccine development.
Moss B
Dev Biol Stand; 1994; 82():55-63. PubMed ID: 7958483
[TBL] [Abstract][Full Text] [Related]
53. Efficacy of systemically administered oncolytic vaccinia virotherapy for malignant gliomas is enhanced by combination therapy with rapamycin or cyclophosphamide.
Lun XQ; Jang JH; Tang N; Deng H; Head R; Bell JC; Stojdl DF; Nutt CL; Senger DL; Forsyth PA; McCart JA
Clin Cancer Res; 2009 Apr; 15(8):2777-88. PubMed ID: 19351762
[TBL] [Abstract][Full Text] [Related]
54. Poxvirus cancer therapy.
Gilbert PA; McFadden G
Recent Pat Antiinfect Drug Discov; 2006 Nov; 1(3):309-21. PubMed ID: 18221156
[TBL] [Abstract][Full Text] [Related]
55. MicroRNA-Detargeted Mengovirus for Oncolytic Virotherapy.
Ruiz AJ; Hadac EM; Nace RA; Russell SJ
J Virol; 2016 Apr; 90(8):4078-4092. PubMed ID: 26865716
[TBL] [Abstract][Full Text] [Related]
56. Efficacy and Safety of Doubly-Regulated Vaccinia Virus in a Mouse Xenograft Model of Multiple Myeloma.
Futami M; Sato K; Miyazaki K; Suzuki K; Nakamura T; Tojo A
Mol Ther Oncolytics; 2017 Sep; 6():57-68. PubMed ID: 28808676
[TBL] [Abstract][Full Text] [Related]
57. Oncolytic bacteria: past, present and future.
Rius-Rocabert S; Llinares Pinel F; Pozuelo MJ; García A; Nistal-Villan E
FEMS Microbiol Lett; 2019 Jun; 366(12):. PubMed ID: 31226708
[TBL] [Abstract][Full Text] [Related]
58. Theranostic potential of oncolytic vaccinia virus.
Rojas JJ; Thorne SH
Theranostics; 2012; 2(4):363-73. PubMed ID: 22509200
[TBL] [Abstract][Full Text] [Related]
59. The next frontier of oncotherapy: accomplishing clinical translation of oncolytic bacteria through genetic engineering.
Dailey KM; Allgood JE; Johnson PR; Ostlie MA; Schaner KC; Brooks BD; Brooks AE
Future Microbiol; 2021 Mar; 16(5):341-368. PubMed ID: 33754804
[TBL] [Abstract][Full Text] [Related]
60. Tumour-targeting bacteria-based cancer therapies for increased specificity and improved outcome.
Felgner S; Pawar V; Kocijancic D; Erhardt M; Weiss S
Microb Biotechnol; 2017 Sep; 10(5):1074-1078. PubMed ID: 28771926
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
